KLRC1 and B-cell chronic lymphocytic leukemia: The use of anti-NKG2A mAbs for therapeutic blockade of NKG2A restored the cytolytic activity of NK cells against HLA-E+ chronic lymphocytic leukemia (CLL) targets, thus improving NK cell dysfunction (54).